Pierce CHOW  
    Main Page                  
a filler
  Pierce CHOW  


a a a
  Pierce CHOW

Brief Biosketch

Pierce Chow is an academic surgeon and Professor at the Duke-NUS Medical School. He is concurrently Senior Consultant Surgeon at the National Cancer Centre Singapore and the Singapore General Hospital, NMRC Senior Clinician Scientist, Adjunct Faculty at the Genome Institute of Singapore and Research Director at the Institute of Cellular and Molecular Biology. He trained in Liver Transplantation with Professor Russell Strong in Australia. In 1998, he co-founded the Asia-Pacific Hepatocellular Carcinoma (AHCC) Trials Group and has been the protocol chair of 5 multi-center clinical trials that have involved more than 30 centers in 14 countries. He was conferred the NMRC National Outstanding Clinician Scientist Award for improving clinical outcomes with his research on Liver Cancer in 2012.

Prof Chow was awarded the NMRC grant for the Translational and Clinical Research (TCR) Flagship Program in Liver Cancer in 2016.  Building on positive results of earlier genetic and immunology studies in surgically resected HCC, Prof Chow now leads a multi-national study on how genomic heterogeneity and the immune micro-environment in HCC impact clinical outcomes. The Program will identify clonally dominant drivers, bring precision medicine to individuals with HCC and initiate new multi-national clinical studies across the Asia Pacific to advance treatment strategies for HCC. In 2017 Prof Chow was awarded the BMRC IAF-PP Grant to develop a patient-specific diagnostic and predictive platform for Precision Medicine in HCC.


Project Description


Patient-specific diagnostic and predictive platform in HCC
– PuRPOSE Programme

Approximately 1 million new cases of hepatocellular carcinoma (HCC) are diagnosed annually and HCC is the 2nd most important cause of cancer deaths. There is only one poorly efficacious systemic drug, Sorafenib and thus a huge unmet clinical need. HCC is highly heterogeneous and for treatment to be effective, it will have to be personalized and targeted - using a patient-specific diagnostic and predictive platform. Such a platform that is scientifically rigorous and clinically validated is currently not available.

This programme leverages on the relative strengths of current programs, in Singapore (the TCR Flagship Program in Liver Cancer and other programs) and in the Republic of Korea (the Refractory Cancer Program at the Samsung Medical Center (SMC) to develop the world's first clinically reliable and robust platform that will fundamentally change and improve the efficacy of HCC treatment. This personalized, targeted patient-specific diagnostic and predictive platform will be developed and validated based on precision analysis, high throughput screening and predictive outcomes using proprietary tissue manipulation techniques, patient derived AVATAR-organoid for in vitro disease simulation and in vivo PDX for therapeutic validation. We will leverage on this high throughput platform to interface with industry for collaborations in drug development and with clinical services to augment therapeutic decisions.

        We aim to:

  • To establish the world’s leading Precision Platform in personalized clinical oncology for HCC
  • To further develop the highly differentiated AVATA Precision Platform for HCC.

Our strategy:

  • Integration of Genomic, Immunomic and Clinical data from patients
  • Scale-up specific patient responses to therapy by leveraging on AVATAR Precision Platform
  • Unique combination of Patient-derived organoid (PDO) and Patient-derived Xenograft (PDX) for drug screening
  • Generation of database with predictive biomarkers for treatment response.
  • Potential to uncover new biomarkers
  • Cutting-edge expertise in PDO for:
  • In vitro disease simulation
  • Immune-competent humanized/cirrhotic mouse models